These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 16029565)

  • 1. [Methotrexate for treatment of graft versus host disease after allogeneic hematopoietic stem cell transplantation].
    Huang XJ; Jiang Q; Chen H; Xu LP; Liu DH; Chen YH; Han W; Zhang YC; Liu KY; Lu DP
    Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(16):1097-101. PubMed ID: 16029565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-dose methotrexate for the treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Huang XJ; Jiang Q; Chen H; Xu L; Liu D; Chen Y; Han W; Zhang Y; Liu K; Lu D
    Bone Marrow Transplant; 2005 Aug; 36(4):343-8. PubMed ID: 15968295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-line therapy for chronic graft-versus-host disease that includes low-dose methotrexate is associated with a high response rate.
    Wang Y; Xu LP; Liu DH; Chen H; Chen YH; Han W; Liu KY; Huang XJ
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):505-11. PubMed ID: 19285639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Influence of graft-versus-host disease on long-term survival of 26 patients with hematologic malignancies after transplantation].
    Lin Q; Dong M; Wang QM; Wen JY; Wu XY
    Ai Zheng; 2006 Oct; 25(10):1261-5. PubMed ID: 17059772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
    Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
    Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Therapeutic efficacy of hematopoietic stem cell transplantation in patients with chronic myelogenous leukemia].
    Liu QF; Fan ZP; Sun J; Zhang Y; Liu XL; Xu D; Xu B; Feng R; Meng FY; Zhou SY
    Di Yi Jun Yi Da Xue Xue Bao; 2004 Nov; 24(11):1227-9, 1241. PubMed ID: 15567763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia].
    Tong XZ; Li J; Tan EX; Zhang GC; Wu XY; Peng AH; Zheng D; Zou WY; Hong WD; Luo SK
    Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation.
    Pérez-Simón JA; Díez-Campelo M; Martino R; Brunet S; Urbano A; Caballero MD; de León A; Valcárcel D; Carreras E; del Cañizo MC; López-Fidalgo J; Sierra J; San Miguel JF
    Br J Haematol; 2005 Aug; 130(3):394-403. PubMed ID: 16042689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase.
    Xiao-Jun H; Lan-Ping X; Kai-Yan L; Dai-Hong L; Huan C; Wei H; Yu-Hong C; Jing-Zhi W; Yao C; Xiao-Hui Z; Hong-Xia S; Dao-Pei L
    Ann Med; 2008; 40(6):444-55. PubMed ID: 18608121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
    Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Liver biopsy in the management of liver dysfunction after allogeneic hematopoietic stem-cell transplantation].
    Chen H; Huang XJ; Liu KY; Xu LP; Wang H; Liu DH; Lu J; Lu DP
    Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(43):3062-6. PubMed ID: 16324408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol.
    Alvarez I; Sureda A; Caballero MD; Urbano-Ispizua A; Ribera JM; Canales M; García-Conde J; Sanz G; Arranz R; Bernal MT; de la Serna J; Díez JL; Moraleda JM; Rubió-Félix D; Xicoy B; Martínez C; Mateos MV; Sierra J
    Biol Blood Marrow Transplant; 2006 Feb; 12(2):172-83. PubMed ID: 16443515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of IL-18 and sIL2R on aGVHD occurrence after hematopoietic stem cell transplantation in some Iranian patients.
    Shaiegan M; Iravani M; Babaee GR; Ghavamzadeh A
    Transpl Immunol; 2006 Jan; 15(3):223-7. PubMed ID: 16431290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early complete donor hematopoietic chimerism in peripheral blood indicates the risk of extensive graft-versus-host disease.
    Balon J; Hałaburda K; Bieniaszewska M; Reichert M; Bieniaszewski L; Piekarska A; Pawłowski R; Hellmann A
    Bone Marrow Transplant; 2005 Jun; 35(11):1083-8. PubMed ID: 15821766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of ethnic minorities with acute or chronic leukemia treated with hematopoietic stem-cell transplantation in the United States.
    Baker KS; Loberiza FR; Yu H; Cairo MS; Bolwell BJ; Bujan-Boza WA; Camitta BM; Garcia JJ; Ho WG; Liesveld JL; Maharaj D; Marks DI; Schultz KR; Wiernik P; Zander AR; Horowitz MM; Keating A; Weisdorf DJ
    J Clin Oncol; 2005 Oct; 23(28):7032-42. PubMed ID: 16145067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transplantation of allogeneic CD34+-selected cells followed by early T-cell add-backs: favorable results in acute and chronic myeloid leukemia.
    Kobbe G; Fenk R; Neumann F; Bernhardt A; Steidl U; Kondakci M; Graef T; Aivado M; Vaupel M; Huenerlituerkoglu AN; Kronenwett R; Pape H; Hildebrand B; Germing U; Haas R
    Cytotherapy; 2004; 6(6):533-42. PubMed ID: 15764020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
    Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [HLA-identical sibling allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia in first chronic phase. Analysis of 51 cases].
    He Y; Feng SZ; Wang M; Wei JL; Qin TJ; Zhou Z; Zhai WJ; Qiu LG; Han MZ
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jul; 26(7):389-92. PubMed ID: 16251016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
    J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hypercholesterolemia as a part of chronic GVHD after allogeneic stem cell transplantation].
    Koyama M; Matsuoka K; Kunisaki Y; Takeuchi M; Matsue K
    Rinsho Ketsueki; 2004 Oct; 45(10):1115-8. PubMed ID: 15553047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.